71dee1fcb13293034d39b410a7a90475c028dc80ab59699cb2187e808da3185d

Product revenues (USD, millions)

Alliance revenues (USD, millions)

Royalty revenues (USD, millions)

Total revenues (USD, millions)

Cost of sales (USD, millions)

Selling, informational and administrative expenses (USD, millions)

Research and development expenses (USD, millions)

Acquired in-process research and development expenses (USD, millions)

Amortization of intangible assets (USD, millions)

Restructuring charges and certain acquisition-related costs (USD, millions)

Other (income)/deductions–net (USD, millions)

Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) (USD, millions)

Provision/(benefit) for taxes on income/(loss) (USD, millions)

Income/(loss) from continuing operations (USD, millions)

Discontinued operations–net of tax (USD, millions)

Net income/(loss) before allocation to noncontrolling interests (USD, millions)

Less: Net income attributable to noncontrolling interests (USD, millions)

Net income/(loss) attributable to Pfizer Inc. common shareholders (USD, millions)

Earnings/(loss) per common share–basic from continuing operations attributable to Pfizer Inc. common shareholders (USD)

Earnings/(loss) per common share–basic from discontinued operations–net of tax (USD)

Net earnings/(loss) per common share–basic attributable to Pfizer Inc. common shareholders (USD)

Earnings/(loss) per common share–diluted from continuing operations attributable to Pfizer Inc. common shareholders (USD)

Earnings/(loss) per common share–diluted from discontinued operations–net of tax (USD)

Net earnings/(loss) per common share–diluted attributable to Pfizer Inc. common shareholders (USD)

Weighted-average shares–basic (millions)

Weighted-average shares–diluted (millions)

02677cadecc7acbfe73cddf51ca24a614e191f529ec9ad9f1bf4ddf242761c08

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from / Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

ce51e61505e23bf58898eb3a07e1f1dfe90caa220b01f0bc7f24730357f30994

983d81601d662bf3d722d258139f82fce4530736d2a81cd08b5763d5f4733b9f

ffbe137c7dcd47e3c305897c8229a07c4947d1b3bf43ba79692c56c898918e31

United States

International

- Developed Markets

- Emerging Markets

Developed Europe

Developed Rest of World

Total Revenue

d315973985a529c4713e17f61fc924d01310dfffae16e25614d8cadbf665646f

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD, Per Share]

EPS - Diluted [USD, Per Share]

4fb5ce67fcd183f9b29ef684321f8ed6fc9d2a01961d0dbe1ba59cffa576e031

Pfizer Inc (PFE)

Financials